|
Title
|
Status
|
|
|
Recruiting
in 5 of 6 locations
|
|
Phase III Metastatic Pancreatic Cancer
|
|
|
Pending
in 1 of 1 locations
|
|
The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.
|
|
|
Recruiting
in 1 of 1 locations
|
|
This study is a Phase III, randomized, open-label, multi-center, prospective study of single
umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric
patients with hematologic malignancies.
|
|
|
Recruiting
in 2 of 3 locations
|
|
This is an open-labeled, continuous daily dosing, two-part safety and efficacy study of
SKI-606 in Philadelphia chromosome positive leukemias (Ph+). Part 1 is a dose-escalation
study in chronic phase Chronic Myelogenous Leukemia (CML) subjects to establish the Maximum
tolerated dose (MTD) in this subject population. Part 2 has begun after the completion of
Part 1 and after a clear MTD has been established for the compound in chronic phase
subjects. Part 2 will include patients in all phases of Ph+ CML and Ph+ Acute Lymphocytic
Leukemia (ALL). The protocol will test the hypotheses that oral daily dosing of SKI-606 at
the MTD, or a lower dose will attain; (1) Major Cytogenetic Response (McyR) in chronic phase
patients and (2) a return to chronic phase in advanced leukemia patients. Each phase of the
disease will be evaluated as a separate cohort.
|
